Table 2 Adjusted results for ROR score continuous (10-point) according to treatment group, and unadjusted HR estimates of the treatment effect of CEF with CMF as reference according to Prosigna ROR scores and subtype.

ROR score, continuous (10-point)

0.056

0.02

0.83

 CMF

1.20

1.09;1.33

1.18

1.07;1.30

1.07

0.98;1.16

 CEF

1.04

0.92;1.18

1.00

0.89;1.13

1.06

0.96;1.16

<10 yrs

1.13

1.03;1.25

0.43

1.07

0.96;1.19

≥10 yrs

0.92

0.79;1.07

0.41

1.01

0.85;1.20

Unadjusted treatment effect of CEF versus CMF

ROR score

0.16

0.10

0.50

≤51

1.01

0.59;1.73

1.04

0.64;1.68

1.05

0.71;1.54

52-71

0.78

0.53;1.15

0.72

0.50;1.05

0.96

0.70;1.31

≥72

0.54

0.36;0.80

0.53

0.36;0.78

0.78

0.55;1.10

Subtype

0.06

0.07^a

0.01

0.07^a

0.03

0.04^a

Luminal A

1.61

0.77;3.35

1.70

0.90;3.23

1.62

0.97;2.71

Luminal B

1.09

0.54;2.19

1.03

0.54;1.97

1.41

0.80;2.47

Basal-like

0.68

0.42;1.08

0.60

0.38;0.94

0.86

0.61;1.21

Her2-enriched

0.57

0.40;0.83

0.56

0.39;0.81

0.72

0.52;0.99